Clinical Trials Sponsored by Peter Lougheed Centre

Total 207 results

University of Calgary
Calgary Adult Bariatric Surgery Clinic; Peter Lougheed Center, Mayfair Diagnostics

Not yet recruiting

Bariatric Embolization Trial for the Obese Nonsurgical (BET-ON)

Obesity | Body Weight | Weight Loss | Morbid Obesity
Peter MacCallum Cancer Centre, Australia

Recruiting

Hepatocellular Carcinoma Imaging Using PSMA PET/CT (HepaSMART)

Hepatocellular Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE)

Follicular Lymphoma

United States, Australia
Peter MacCallum Cancer Centre, Australia

Suspended

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH)

Hodgkin Lymphoma

Australia, New Zealand
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours (RAPPORT)

Renal Cell Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia

Completed

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO)

Adenoid Cystic Carcinoma | Colorectal Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Completed

A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases (FASTRACK)

Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Unknown

Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome

Multiple Myeloma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Metabolic Phenotypes in Melanoma (MetaMel)

Melanoma

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB)

Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary (FAPI-CUP)

Cancer of Unknown Primary Site

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study (PRIME_LUNG)

NSCLC

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders. (EMBRACE)

Aplastic Anemia | Bone Marrow Failure Syndrome

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA)

Metastatic Triple Negative Breast Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN)

Breast Neoplasm Female

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Peter MacCallum Cancer Centre, Australia

Completed

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; (C-SMART)

Cancer | Covid19 | Respiratory Viral Infection

Australia
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia

Completed

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)

Metastatic Castration Resistant Prostate Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Terminated

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR)

Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (EpiBrentlen)

Hodgkin Lymphoma | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

Australia
Peter MacCallum Cancer Centre, Australia

Completed

A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours (LeY-CAR-T)

Advanced Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 (BOSTON II)

Breast Neoplasms | Bone Neoplasms

Australia
Peter MacCallum Cancer Centre, Australia

Completed

A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer

Malignant Rectal Neoplasm | Recurrent Tumor

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions (SPECIFIC)

Invasive Fungal Infections

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer (AlphaBet)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)

Neuroendocrine Tumors

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER)

Renal Cell Carcinoma, Clear Cell, Somatic

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

ProsTIC Registry of Men Treated With PSMA Theranostics

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)

Melanoma | Metastasis

Australia
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T (VIOLET)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Terminated

Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

Squamous Cell Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

Rectal Cancer

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq)

Non-small Cell Lung Cancer

Australia, Canada
Peter MacCallum Cancer Centre, Australia

Completed

High Intensity Functional Image Guided Vmat Lung Evasion (HI-FIVE)

Non Small Cell Lung Cancer Stage III

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Panobinostat Biological Correlates Study (VEG VCA1)

Multiple Myeloma | Nodal Lymphoma | Lymphoma With Cutaneous Involvement | Lymphoma in Leukemic Phase | Marrow Involvement With Lymphoma

Australia
Peter MacCallum Cancer Centre, Australia

Terminated

A Study of APR-246 in Oesophageal Cancer (APROC)

Oesophageal Carcinoma

Australia
Peter MacCallum Cancer Centre, Australia

Completed

A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer

Rectal Cancer

Australia
Peter MacCallum Cancer Centre, Australia
Novartis

Active, not recruiting

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Mantle Cell Lymphoma Recurrent

Australia
Peter Gæde

Active, not recruiting

Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria (Steno-2)

Type 2 Diabetes

Denmark
Peter Rossing

Completed

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (DapKid)

Diabetic Nephropathy | Type 2 Diabetes

Denmark
Peter Wijkstra

Recruiting

The Effects of Nocturnal Non-invasive Ventilation in Stable COPD (RECAPTURE)

Noninvasive Ventilation

Netherlands
Peter Anderson

Completed

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor | Recurrent Neuroendocrine Tumor

United States
Peter Rossing

Completed

Microalbuminuria and Allopurinol in Type 1 Diabetes (MIKAL)

Type 1 Diabetes | Diabetic Nephropathy

Denmark
Peter Rossing

Completed

PeRsOnalising Treatment Of Diabetic Nephropathy: (PROTON)

Diabetes Complications | Diabetes Mellitus, Type 1 | Diabetic Nephropathies

Denmark
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia

Clinical Trials Sponsored by Peter Lougheed Centre

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations